Stay updated on Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page
- Check7 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a Phase II study involving pembrolizumab for treating relapsed or refractory lymphomas, while adding new collaborators and a revision update.SummaryDifference34%
- Check14 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check29 days agoChange DetectedDifference0.4%
- Check36 days agoChange DetectedDifference0.5%
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Pembrolizumab Post-ASCT in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-ASCT in Lymphoma Clinical Trial page.